SignalSilence ® Stat1 siRNA I from Cell Signaling Technology

Product Specs
ItemSignalSilence ® Stat1 siRNA I
CompanyCell Signaling Technology
Price $369.00 Inquire
Catalog Number6331S
Quantity300 µl
TargetStat1
NCBI Gene AliasesCANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91
NCBI Full Gene Namesignal transducer and activator of transcription 1
Research AreaImmunology and Inflammation
Molecular Weight84, 91
ReactivityH
ApplicationssiRNA
TypesiRNA

Add to Compare List

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Secretoneurin A regulates neurogenic and inflammatory transcriptional networks in goldfish (Carassius auratus) radial gliaScientific ReportsDecember 1, 2017Dillon F. Da Fonte, Christopher J. Martyniuk, Lei Xing, Adrian Pelin, Nicolas Corradi, Wei Hu, Vance L. Trudeau

(2) UVB-induced nuclear translocation of TC-PTP by AKT/14-3-3σ axis inhibits keratinocyte survival and proliferationOncotargetOctober 31, 2017Kim M, Morales LD, Baek M, Slaga TJ, DiGiovanni J, Kim DJ.Tzivion G, Shen YH, Zhu J. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene. 2001; 20: 6331-8. 39. Kraut J, Volohonsky G, Toledano-Katchalski H, Elson A. Nuclear localization of non-receptor

(3) NF-κB regulates neuronal ankyrin-G via a negative feedback loopScientific reportsFebruary 9, 2017König HG, Schwamborn R, Andresen S, Kinsella S, Watters O, Fenner B, Prehn JH.

(4) Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon AlphaCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacologyJanuary 1, 2016Zhao LJ, He SF, Liu Y, Zhao P, Bian ZQ, Qi ZT.Interferon Source. Jak inhibitor I was from Merck (Calbiochem, Darmstadt, Germany). STAT1 siRNA (Catalog no. 6331) and control siRNA (Catalog no. 6568) were from Cell Signaling Technology. Products used for cell culture

(5) PtdIns(4,5)P2-Mediated Cell Signaling: Emerging Principles and PTEN as a Paradigm for Regulatory MechanismAdvances in Experimental Medicine and BiologyJuly 11, 2013Arne Gericke, Nicholas R. Leslie, Mathias LÃ¶sche, Alonzo H. RossManuscript Published in final edited form as: Adv Exp Med Biol. 2013 ; 991: 85–104. doi:10.1007/978-94-007-6331-9_6. PI(4,5)P2-Mediated Cell Signaling: Emerging Principles and PTEN as a Paradigm for Regulatory Mechanism Arne

(6) Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo ActivitiesJournal of Cancer Science & TherapyJuly 2, 2010Chandra S S Boosani, Ashok K K Verma, Akulapalli SudhakarNational Research Hospital, 555 N, 30th Street, Omaha NE 68131, Tel: (402) 498-6681, (402) 498-6322; Fax: (402) 498-6331; E-mail: akulapallis@boystown.org Received November 19, 2009; Accepted November 27, 2009; Online published

(7) RETRACTED ARTICLE: Inhibitory Effects of Arresten on bFGF-Induced Proliferation, Migration, and Matrix Metalloproteinase-2 Activation in Mouse Retinal Endothelial CellsCurrent Eye ResearchFebruary 9, 2010Chandra Shekar Boosani, Narasimharao Nalabothula, Nader Sheibani, Akulapalli Sudhakar555 N, 30th Street, Omaha NE 68131, USA., Office: (402) 498-6681, Lab: (402) 498-6322, Fax: (402) 498-6331, akulapallis@boystown.org. *These authors contributed equally to this work Declaration of Interest:

(8) History of Cancer, Ancient and Modern Treatment MethodsJournal of Cancer Science & TherapyDecember 1, 2009Akulapalli SudhakarNational Research Hospital, 555 N, 30th Street, Omaha NE 68131 USA, Tel: # (402) 4986681; Fax: (402) 498-6331; E-mail: akulapallis@boystown.org Received December 21, 2009; Accepted December 26, 2009; Online published

(9) FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1Investigative Opthalmology & Visual ScienceOctober 1, 2009Chandra S. Boosani, Narasimharao Nalabothula, Veerendra Munugalavadla, Dominic Cosgrove, Venkateshwar G. Keshamouni, Nader Sheibani, Akulapalli Sudhakar555 N, 30th Street, Omaha NE 68131, USA., Office: (402) 498-6681; Lab: (402) 498-6322; Fax: (402) 498-6331, akulapallis@boystown.org. Î¹These authors contributed equally to this work Boosani et al. Page

(10) The Matrix Reloaded: New Insights from Type IV Collagen Derived Endogenous Angiogenesis Inhibitors and their Mechanism of ActionJournal of Bioequivalence & BioavailabilityJanuary 1, 2009Akulapalli SudhakarHospital, 555 N, 30th Street, Omaha NE 68131, USA, Tel: (402) 498-6681, (402) 498-6322; Fax: (402) 498-6331; E-mail: akulapallis@boystown.org Received August 19, 2009; Accepted August 21, 2009; Published August

(11) Molecular Cloning and Functional Characterization of Mouse Î±3(IV)NC1Clinical medicine. OncologyJanuary 1, 2008Chandra Shekhar Boosani, Akulapalli SudhakarNational Research Hospital, 555, North 30th street, Omaha, NE 68131. Tel: 402-498-6681; Fax: 402-498-6331; Email: akulapallis@boystown.org Copyright in this article, its metadata, and any supplementary data

(12) Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrinJournal of Clinical InvestigationOctober 1, 2005Akulapalli Sudhakar, Pia Nyberg, Venkateshwar G Keshamouni, Arjuna P Mannam, Jian Li, Hikaru Sugimoto, Dominic Cosgrove, Raghu KalluriHospital, 555 North 30th Street, Omaha, Nebraska 68131, USA. Phone: (402) 498-6681; Fax: (402) 498-6331; E-mail: akulapallis@boystown.org. Akulapalli Sudhakar and Pia Nyberg contributed equally to this work. Cell.

Be the First to Write a Review!